All Drugs in Clinical Trials in 2023 Research/Science 1/9/2023
12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.
View this post in the Community β
Similar Community Posts Join
5 / 431 resultscommunity Kintorβs KX-826 Pyrilutamide!!
KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.
community What new hair-loss treatments actually look exciting right now (Oct 2025)
New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.
community Pyrilutamide ,the molecule’s true nature
Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.
community Kintor Has Completed Enrollment in Phase II Clinical Trial of KX-826 (Pyrilutamide) for Treatment of Male AGA Patients in the US
KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.
community New Hair Loss Treatment from Kintor Just Hit the Market: KX-826!
Kintor Pharmaceutical's new hair loss treatment, KX-826, is entering the market. Users are eager to see its effectiveness before celebrating.
Related Research
6 / 178 results
research Recent Advances in Drug Development for Hair Loss
New treatments for hair loss show promise with advanced therapies and better targeting.
research Efficacy and Safety of Topical KX-826 in Male Subjects with Androgenetic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study
KX-826 is safe and effectively increases hair count in men with hair loss.
research Development and Validation of Androgen-Induced Hair Loss and Anagen Induction Mouse Models for Pharmacological Evaluation of Anti-Androgenic Agents
The mouse models are effective for testing new hair loss treatments.
research A Decade of Progress in Androgenetic Alopecia Management: Emerging Therapies and Multimodal Strategies
Androgenetic alopecia treatments are becoming more personalized and include new therapies like topical antiandrogens and regenerative strategies.
research The 100 Most Cited Articles in Androgenetic Alopecia: A Bibliometric Analysis
Recent research on androgenetic alopecia focuses on optimizing treatments, with promising new therapies emerging.
research Mechanism Exploration of the Combined Use of Minoxidil with Natural Compounds Ginsenoside Rg3 and Glycyrrhizic Acid for Enhancing Androgenic Alopecia Therapy
Combining minoxidil with ginsenoside Rg3 and glycyrrhizic acid offers a more effective treatment for androgenic alopecia.